Author

Karen Silence

Observed names: K Silence, K. SILENCE, K. Silence, Silence Karen, Silence, Karen

Observed institutions: Ablynx (Belgium), Vrije Universiteit Brussel, Inserm, Utrecht University, Vlaams Instituut voor Biotechnologie, University Medical Center Utrecht, Argenx (Belgium), KU Leuven

OpenAlex ID: A5015773919

Molecular basis for the preferential cleft recognition by dromedary heavy-chain antibodies

2006 · Erwin De Genst, Karen Silence, et al. · Proceedings of the National Academy of Sciences · 680

Formatted anti–tumor necrosis factor α VHH proteins derived from camelids show superior potency and targeting to inflamed joints in a murine model of collagen‐induced arthritis

2006 · Ken Coppieters, Torsten Dreier, et al. · Arthritis & Rheumatism · 303

CD70: An emerging target in cancer immunotherapy

2015 · J. Jacobs, V. Deschoolmeester, et al. · Pharmacology & Therapeutics · 206

Antithrombotic drug candidate ALX-0081 shows superior preclinical efficacy and safety compared with currently marketed antiplatelet drugs

2011 · Hans Ulrichts, Karen Silence, et al. · Blood · 185

A novel nanobody that detects the gain-of-function phenotype of von Willebrand factor in ADAMTS13 deficiency and von Willebrand disease type 2B

2005 · Janine J. J. Hulstein, Philip G. de Groot, et al. · Blood · 151

PDF

Acute activation of the endothelium results in increased levels of active von Willebrand factor in hemolysis, elevated liver enzymes and low platelets (HELLP) syndrome

2006 · J.J.J. HULSTEIN, P.J. VAN RUNNARD HEIMEL, et al. · Journal of Thrombosis and Haemostasis · 130

ARGX-110, a highly potent antibody targeting CD70, eliminates tumors via both enhanced ADCC and immune checkpoint blockade

2013 · Karen Silence, Torsten Dreier, et al. · mAbs · 103

PDF

Bivalent Llama Single-Domain Antibody Fragments against Tumor Necrosis Factor Have Picomolar Potencies due to Intramolecular Interactions

2017 · Els Beirnaert, Aline Desmyter, et al. · Frontiers in Immunology · 87

PDF

CD 70 and PD ‐L1 in anaplastic thyroid cancer – promising targets for immunotherapy

2017 · Karen Zwaenepoel, Julie Jacobs, et al. · Histopathology · 68

Phase I Dose-Escalation Study of the Anti-CD70 Antibody ARGX-110 in Advanced Malignancies

2017 · Philippe Aftimos, Christian Rolfo, et al. · Clinical Cancer Research · 66

Recombinant Staphylokinase Variants With Altered Immunoreactivity

1996 · De´sire´ Collen, Ria Bernaerts, et al. · Circulation · 65

Isolation and characterisation of natural and recombinant staphylokinase

1992 · D. Collen, K. Silence, et al. · Fibrinolysis and Proteolysis · 63

Unlocking the potential of CD70 as a novel immunotherapeutic target for non-small cell lung cancer

2015 · Julie Jacobs, Karen Zwaenepoel, et al. · Oncotarget · 59

PDF

Strong in Vivo Maturation Compensates for Structurally Restricted H3 Loops in Antibody Repertoires

2005 · Erwin De Genst, Karen Silence, et al. · Journal of Biological Chemistry · 59

PDF

ARGX-117, a therapeutic complement inhibiting antibody targeting C2

2020 · Inge Van de Walle, Karen Silence, et al. · Journal of Allergy and Clinical Immunology · 54

PDF

Structure-Function Relationships in Staphylokinase as Revealed by "Clustered Charge to Alanine" Mutagenesis

1995 · Karen Silence, Manfred Hartmann, et al. · Journal of Biological Chemistry · 43

Interaction between staphylokinase, plasmin(ogen), and alpha 2-antiplasmin. Recycling of staphylokinase after neutralization of the plasmin-staphylokinase complex by alpha 2-antiplasmin

1993 · K. Silence, D. Collen, et al. · Journal of Biological Chemistry · 42

Depleting MET-Expressing Tumor Cells by ADCC Provides a Therapeutic Advantage over Inhibiting HGF/MET Signaling

2015 · Anna Hultberg, Virginia Morello, et al. · Cancer Research · 41

PDF

Cusatuzumab for treatment of CD70‐positive relapsed or refractory cutaneous T‐cell lymphoma

2021 · Nicolas Leupin, Pier Luigi Zinzani, et al. · Cancer · 35

CD70-restricted specific activation of TRAILR1 or TRAILR2 using scFv-targeted TRAIL mutants

2014 · J Trebing, M El-Mesery, et al. · Cell Death and Disease · 32

PDF

ARGX-119 is an agonist antibody for human MuSK that reverses disease relapse in a mouse model of congenital myasthenic syndrome

2024 · Roeland Vanhauwaert, Julien Oury, et al. · Science Translational Medicine · 31

PDF

Regulation by alpha 2-antiplasmin and fibrin of the activation of plasminogen with recombinant staphylokinase in plasma

1993 · K Silence, D Collen, et al. · Blood · 28

A novel llama antibody targeting Fn14 exhibits anti-metastatic activity in vivo

2013 · Johannes Trebing, Isabell Lang, et al. · mAbs · 26

PDF

Agonist antibody to MuSK protects mice from MuSK myasthenia gravis

2024 · Julien Oury, Begona Gamallo-Lana, et al. · Proceedings of the National Academy of Sciences · 21

PDF

Anti-C2 Antibody ARGX-117 Inhibits Complement in a Disease Model for Multifocal Motor Neuropathy

2022 · Budding, Kevin, Johansen, Lill Eva, et al. · Utrecht University Repository (Utrecht University) · 17

Works count: 71

Citation count: 2,700

H-index: 23

I10-index: 30